Advertisement
To access the live webcast or the subsequent archived recording, log on tohttp://www.anesiva.com, go to the Investors page, and click on Events. Pleaseconnect to Anesiva's website several minutes prior to the start of the webcastto ensure adequate time for any software download that may be necessary. Thearchived recording will be available from approximately 7:30 pm ET onSeptember 24 through October 23, 2008.
Advertisement
About Anesiva and its Diverse Pipeline of Pain Products
Anesiva, Inc. is a commercial-stage specialty pharmaceutical company thatseeks to be a leader in the development and commercialization of novelpharmaceutical products for pain management. The company's first commercialproduct, Zingo(TM) (lidocaine hydrochloride monohydrate 0.5 mg) powderintradermal injection system, is available in the U.S. for the reduction ofpain associated with peripheral venous access procedures in children agesthree to 18. For full Zingo prescribing information and other information,visit http://www.zingo.com. An application is under FDA review to expand theZingo label indication to include adults.
The next product in Anesiva's pipeline, Adlea(TM), is currently beingevaluated in multiple clinical trials for the management of acute painfollowing orthopedic surgeries. Adlea has been shown in Phase 2 trials toreduce pain after only a single administration for weeks to months in multipleindications for site-specific, acute and chronic, moderate-to-severe pain.
Anesiva is based in South San Francisco, CA. For more information aboutAnesiva's leadership in the development and commercialization of products forpain management, and an overview of the clinical progress of its productcandidates, go to http://www.anesiva.com.
SOURCE Anesiva, Inc.
